Equities

Synaptogenix Inc

SNPX:NAQ

Synaptogenix Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.71
  • Today's Change-0.38 / -7.47%
  • Shares traded57.99k
  • 1 Year change-78.09%
  • Beta1.5170
Data delayed at least 15 minutes, as of May 06 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Synaptogenix, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for neurodegenerative disorders. The Company is principally focused on developing a product platform based upon a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing. It has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in AD.

  • Revenue in USD (TTM)0.00
  • Net income in USD-13.78m
  • Incorporated2012
  • Employees5.00
  • Location
    Synaptogenix Inc1185 AVENUE OF THE AMERICAS, 3RD FLOORNEW YORK 10036United StatesUSA
  • Phone+1 (973) 242-0005
  • Fax+1 (302) 655-5049
  • Websitehttps://www.synaptogen.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shineco Inc4.50m-13.99m5.32m87.00--0.0136--1.18-3.93-4.630.443160.930.05580.39320.984451,761.38-18.99-12.77-34.44-16.8411.9425.88-340.48-102.060.4903-9.040.3792-----58.35-33.86------
Portage Biotech Inc0.00-144.90m5.36m7.00--0.1675-----7.96-7.960.001.620.00----0.00-111.60-19.70-113.27-26.48------------0.0087-------520.10------
Emmaus Life Sciences Inc28.46m-4.74m5.36m55.00------0.1885-0.0931-0.09310.3905-0.67730.63490.81849.36517,454.50-10.58------93.69---16.66--0.12490.1426-----10.77--33.37------
ProtoKinetix, Inc.0.00-415.48k5.40m0.00--12.38-----0.0012-0.00120.000.00130.00-------88.08-696.88-96.94-785.51------------0.00------78.22--10.78--
Halberd Corp281.24k25.34k5.40m3.003.66--213.0419.220.00230.00230.0018-0.00020.14490.03032.52--1.31--4.58--50.00--9.01--0.26611.351.02--271.52---60.11------
Psycheceutical Bioscience Inc1.16m-149.52k5.45m4.00--0.058--4.71-0.1157-0.11570.89530.33990.630898.602.34289,232.50-8.15---29.82--60.50---12.92--0.959--0.0906-------1,100.34------
NLS Pharmaceutics AG0.00-15.47m5.46m2.00---------0.534-0.5340.00-0.13220.00----0.00-714.74-308.05---------------175.42---------38.08------
Fresh Tracks Therapeutics Inc8.01m-5.69m5.50m4.00--0.5535--0.6865-1.38-1.381.491.660.7326----2,001,500.00-52.10-89.76-66.50-115.24-----71.12-442.61---1,272.000.00--15.3137.6273.02------
Synaptogenix Inc0.00-13.78m5.52m5.00--0.2015-----43.56-43.560.0026.550.00----0.00-17.32-40.33-18.83-43.36------------0.00-------142.17---3.21--
Enzon Pharmaceuticals Inc0.0098.00k5.57m0.0056.821.59----0.00130.00130.000.61970.00------2.88-0.86542.99-0.8851-------159.43----0.00---100.00--106.71-55.86----
Burzynski Research Institute Inc0.00-1.19m5.62m2.00---------0.009-0.0090.00-0.00030.00-------84,895.00-10,098.54------------------------6.18------
Seelos Therapeutics Inc2.20m-37.88m5.64m15.00------2.56-8.95-8.950.4402-3.420.1564----146,866.70-269.01-180.05---386.76-----1,719.56-9,612.88------------48.48------
Protagenic Therapeutics Inc0.00-5.00m5.68m----1.55-----1.15-1.150.000.82710.00-------80.91-74.49-94.48-92.56-----------9.560.00-------40.64------
Sonnet Biotherapeutics Holdings Inc129.19k-14.46m5.71m12.00--2.22--44.20-12.91-12.910.06760.83810.0251--0.168810,765.83-281.29-----------11,192.09------0.00---57.76--36.64------
Integrated BioPharma, Inc.50.52m-385.00k5.74m141.00--0.309--0.1136-0.0128-0.01281.680.61681.954.2112.26358,269.50-1.4915.51-1.8927.946.6212.09-0.76216.440.8428-22.530.0015---9.913.00-101.35---14.03--
Soligenix Inc839.36k-6.14m5.76m13.00--1.66--6.86-0.9164-0.91640.10850.2430.0697--5.8664,566.15-51.01-75.40-872.23-154.3211.5922.83-731.60-620.02---1,677.110.5639---11.54-30.6755.50------
Data as of May 06 2024. Currency figures normalised to Synaptogenix Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.